Diabetes Therapy Breakthrough: Recent buzz on social media has centered around Genprex, Inc.'s latest preclinical data for GPX-002, a gene therapy targeting Type 2 diabetes. Many users are excited about the reported success in normalizing glucose levels in animal studies. The potential for a novel treatment has sparked lively conversations.
Clinical Milestones Ahead: Discussions also highlight the company’s updates on upcoming milestones, including FDA engagements planned for 2026. There’s a sense of anticipation about how these developments could impact the stock’s future. Some express hope for accelerated progress in the diabetes therapy space.
Nasdaq Compliance Relief: Another point of focus is the recent news of Genprex meeting Nasdaq’s stockholders’ equity requirements. Social media chatter reflects relief over the removal of delisting risks. This update has added a layer of optimism to the ongoing dialogue.
Note: This discussion summary was generated from an AI condensation of post data.
Genprex, Inc. Congressional Stock Trading
Members of Congress have traded $GNPX stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GNPX stock by members of Congress over the last 6 months:
- REPRESENTATIVE TIM MOORE has traded it 3 times. They made 3 purchases worth up to $80,000 on 12/18, 11/07, 10/29 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Genprex, Inc. Hedge Fund Activity
We have seen 3 institutional investors add shares of Genprex, Inc. stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC added 205,180 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,737,874
- UBS GROUP AG removed 127,995 shares (-97.5%) from their portfolio in Q3 2025, for an estimated $21,682
- GEODE CAPITAL MANAGEMENT, LLC removed 71,923 shares (-95.6%) from their portfolio in Q3 2025, for an estimated $12,183
- VIRTU FINANCIAL LLC removed 43,103 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,301
- FREEDOM INVESTMENT MANAGEMENT, INC. removed 16,580 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,808
- HUB INVESTMENT PARTNERS, LLC removed 15,160 shares (-97.8%) from their portfolio in Q3 2025, for an estimated $2,568
- HIGHTOWER ADVISORS, LLC removed 14,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,371
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
